Leadership

Mayo Clinic Names AI Program Director Callstrom as Next CEO

Mayo Clinic trustees elected AI Program director Matthew Callstrom as president and CEO on November 13, 2026; he succeeds Gianrico Farrugia at year-end.

By Olivia Hart

4 min read

Mayo Clinic: Matthew Callstrom Named President And CEO, Succeeding Gianrico Farrugia
Mayo Clinic: Matthew Callstrom Named President And CEO, Succeeding Gianrico FarrugiaBru-nO / pixabay

What's News

  • Mayo Clinic's Board of Trustees elected Matthew R. Callstrom president and CEO on November 13, 2026.
  • Callstrom succeeds Gianrico Farrugia, who remains CEO through December 31, 2026.
  • Callstrom has spent nearly 25 years at Mayo Clinic since joining in 2002 and directs its AI Program.
  • His research has produced more than 200 publications and patents in image-guided cancer treatment.
  • Farrugia has served as president and CEO since 2019, leading the Bold. Forward. strategy.

By Olivia Hart

Mayo Clinic has elected Matthew R. Callstrom, M.D., Ph.D. — the physician-scientist who currently runs the organization's artificial intelligence strategy — as its next president and CEO. The Mayo Clinic Board of Trustees announced the appointment on November 13, 2026. Callstrom will succeed Gianrico Farrugia, M.D., who stays in the role through December 31, 2026, to manage the handover.

The choice puts a 25-year insider with deep technology credentials at the top of one of the largest nonprofit medical organizations in the United States. Callstrom joined Mayo Clinic in 2002. He serves today as medical director for Mayo Clinic Strategy and its AI Program, and he sits on both the Board of Governors and the Board of Trustees.

That dual role — governing the institution while running its AI agenda — concentrates considerable authority in one office. The board, notably, did not disclose the terms of Callstrom's compensation or the process behind his selection. Boards rarely do, but the omission still limits what outsiders can judge about the decision.

Who is Matthew Callstrom?

Callstrom is a body interventional radiologist internationally recognized for advancing image-guided cancer treatments. His research centers on technologies that improve the precision of cancer detection and treatment. That work has produced more than 200 publications and patents — roughly eight per year over his tenure — alongside leadership of and collaboration on numerous clinical trials.

His prior posts include interim chief strategy officer and chair of the Department of Radiology at Mayo Clinic in Rochester, Minnesota. He served as president of the Society of Interventional Oncology and holds the distinction of Mayo Clinic Distinguished Clinician.

His academic path runs from chemical engineering and chemistry degrees at the University of Minnesota Twin Cities, through a postdoctoral fellowship at Harvard University, to a medical degree from Mayo Clinic Alix School of Medicine. He then completed his diagnostic radiology residency and a cross-sectional imaging fellowship at Mayo Clinic in Rochester. In short: he trained inside the institution he will now lead.

What does the appointment signal about AI in healthcare?

The timing matters. Mayo Clinic is expanding its use of artificial intelligence across clinical care, research and healthcare delivery, and it picked the executive directing that expansion to run the enterprise. As AI Program medical director, Callstrom has pushed applications designed to speed up treatment discovery, catch diseases earlier and give clinicians added capabilities against complex conditions.

The organization is also building Mayo Clinic Platform, an AI-enabled initiative intended to connect clinical data, research and technology in support of new care models. Mayo Clinic says Callstrom is expected to build on these initiatives while advancing the broader strategy. What remains unstated is how these programs will be measured — the announcement offers no adoption figures, outcomes data or financial metrics for the AI work.

What did the board and the principals say?

Board of Trustees Chair Richard K. Davis framed the appointment around translation — turning science into patient benefit. "Dr. Callstrom is an accomplished physician-scientist and enterprise leader who brings nearly 25 years of experience at Mayo Clinic and a deep commitment to our values and mission," Davis said. "His leadership across patient care, research, strategy and innovation, combined with his ability to translate scientific discovery and emerging technology into meaningful advances for patients, prepares him exceptionally well to lead Mayo Clinic into its next chapter."

Callstrom emphasized scale and speed. "Mayo Clinic has always been at its best when we bring the full power of our clinical expertise, science and innovation to the needs of the patient," he said. "Now, we have an opportunity to build on that foundation – accelerating the translation of discovery and emerging technologies into better care and extending Mayo Clinic's impact to more patients, wherever they are."

Farrugia, president and CEO since 2019, endorsed his successor. "Dr. Callstrom knows Mayo Clinic deeply, understands where healthcare is headed and has the vision and experience to build on the progress we have made," Farrugia said. "I have great confidence in him and in Mayo Clinic's future."

What legacy does Callstrom inherit?

Farrugia's seven-year tenure centered on the Bold. Forward. strategy: accelerating medical discovery, translating research into clinical applications, connecting healthcare data and developing scalable care delivery models. The strategy also funded physical and digital infrastructure, research, education, AI and new approaches to patient care. The board credited Farrugia with significant organizational transformation while keeping patients first — though, again, without attaching numbers to that claim.

Farrugia will work closely with Callstrom through the end of 2026 to ensure an orderly transition.

Mayo Clinic operates as a nonprofit spanning hospitals, medical facilities, research programs and education across the United States and internationally. The bet embedded in this succession is clear: an internal physician-scientist who already directs the AI agenda will now decide how fast, and how far, Mayo Clinic pushes technology into medicine.

Source: pulse2.com

Share this article:

More from Olivia Hart

Olivia Hart

Show full bio

Staff writer covering people, launches and day-to-day practice in entrepreneurship, startups and venture funding at Business Bearings.

2,221 articles

Related articles

« Previous articleNext article »